Pasithea Therapeutics Corp
(NASDAQ:KTTA)
$0.3199
-0.0094[-2.85%]
Last update: 5:43PM (Delayed 15-Minutes)
Get Real Time Here
$0.3199
0[0.00%]
After-Hours
Open0.311Close0.300
Vol / Avg.8.334K / 40.579KMkt Cap6.666M
Day Range0.300 - 0.32852 Wk Range0.286 - 1.030

Pasithea Therapeutics Stock (NASDAQ:KTTA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$2.00

Lowest Price Target1

$2.00

Consensus Price Target1

$2.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20000

Analyst Firms Making Recommendations1

  • EF Hutton

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Pasithea Therapeutics

Upgrades (0)

Downgrades (0)

Initiations (1)

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
07/10/2023KTTABuy Now
Pasithea Therapeutics
$0.30566.44%EF Hutton
Elemer Piros
→ $2ReiteratesBuy → BuyGet Alert
06/01/2023KTTABuy Now
Pasithea Therapeutics
$0.30566.44%EF Hutton
Elemer Piros
→ $2Assumes → BuyGet Alert
04/03/2023KTTABuy Now
Pasithea Therapeutics
$0.30566.44%EF Hutton
Constantine Davides
$2.3 → $2MaintainsBuyGet Alert
12/14/2021KTTABuy Now
Pasithea Therapeutics
$0.30982.97%EF Hutton
Constantine Davides
Initiates → BuyGet Alert
Q

What is the target price for Pasithea Therapeutics (KTTA)?

A

The latest price target for Pasithea Therapeutics (NASDAQ: KTTA) was reported by EF Hutton on July 10, 2023. The analyst firm set a price target for $2.00 expecting KTTA to rise to within 12 months (a possible 525.20% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Pasithea Therapeutics (KTTA)?

A

The latest analyst rating for Pasithea Therapeutics (NASDAQ: KTTA) was provided by EF Hutton, and Pasithea Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Pasithea Therapeutics (KTTA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pasithea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pasithea Therapeutics was filed on July 10, 2023 so you should expect the next rating to be made available sometime around July 10, 2024.

Q

Is the Analyst Rating Pasithea Therapeutics (KTTA) correct?

A

While ratings are subjective and will change, the latest Pasithea Therapeutics (KTTA) rating was a reiterated with a price target of $0.00 to $2.00. The current price Pasithea Therapeutics (KTTA) is trading at is $0.32, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.